GlassScriptPhysician profile
Matthew Barros
NPI 1164886735
$881.22
in general payments reported to CMS, 2019-2025
12 companies · $19.71 in 2025
The $19.71 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $86.16 · 2021: $210 · 2022: $307 · 2023: $259 · 2025: $19.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $278.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $140.13 | 2020-2021 | |
| Axogen | $127.50 | 2023 | Avance Nerve Graft |
| Abbvie INC. | $123.60 | 2022 | |
| Boston Scientific Corporation | $118.56 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $85.28 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $82.79 | 2023 | Quviviq |
| Novo Nordisk INC | $81.51 | 2021 | |
| Janssen Pharmaceuticals, INC | $51.68 | 2020-2022 | |
| Amgen INC. | $19.71 | 2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.27 | 2020 | |
| Breas Medical, INC. | $18.22 | 2023 | Vivo 45 Ls |
| Astrazeneca Pharmaceuticals LP | $12.97 | 2023 | Lokelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Barros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.